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ABSTRACT 39 
 40 
Importance – Whether conservative management is superior to interventional treatment 41 
(‘intervention’) for unruptured brain arteriovenous malformations (bAVMs) is uncertain, because 42 
of the shortage of long-term comparative data. 43 
Objective – Long-term comparison of outcomes of conservative management versus intervention 44 
for unruptured bAVM. 45 
Design – Population-based inception cohort study of adults resident in Scotland, first diagnosed 46 
with an unruptured bAVM during 1999-2003 or 2006-2010, and followed prospectively using 47 
multiple sources to assess handicap and to identify and validate outcome events over 12 years of 48 
prospective follow-up. 49 
Exposures – We compared associations with conservative management (without intervention) 50 
versus intervention (endovascular embolization ± neurosurgical excision ± stereotactic 51 
radiosurgery). 52 
Main outcomes and measures – Cox regression analyses, with multivariable adjustment for 53 
prognostic factors and baseline imbalances if hazards were proportional, to compare rates of the 54 
primary outcome (death or sustained morbidity of any cause, Oxford Handicap Scale score [OHS] 55 
≥2 for at least two successive years [0=no symptoms and 6=death]) and the secondary outcome 56 
(non-fatal symptomatic stroke or death due to bAVM, associated arterial aneurysm or 57 
intervention). 58 
Results – Of 204 adults, 101 underwent intervention; they were younger, more likely to have 59 
presented with seizure(s), and less likely to have large bAVMs than adults managed conservatively. 60 
During a median follow-up of 6·9 years (94% completeness), the rate of progression to the primary 61 
outcome was lower with conservative management during the first four years of follow-up [16 62 
deaths (4.0 per 100 person-years) and 20 OHS 2-5 (5.5 per 100 person-years) versus 4 deaths (1.0 63 
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per 100 person-years) and 35 OHS 2-5 (8.8 per 100 person-years), adjusted hazard ratio (HR) 0·59, 64 
95% confidence interval (CI) 0·35 to 0·99], but rates were similar thereafter. The rate of the 65 
secondary outcome was lower with conservative management during 12 years of follow-up [14 66 
events (1.6 per 100 person-years) versus 38 events (3.3 per 100 person-years), adjusted HR 0·37, 67 
95% CI 0·19 to 0·72]. 68 
Conclusions and relevance – Among adults diagnosed with unruptured bAVM, the use of 69 
conservative management compared with intervention was associated with better clinical 70 
outcomes over 4 years. Longer follow-up is required to understand whether this association 71 
persists.72 
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INTRODUCTION 73 
 74 
Unruptured brain arteriovenous malformations and their associated feeding/nidal arterial 75 
aneurysms (collectively termed ‘bAVM’) have ~1% annual risk of intracranial hemorrhage,1,2 which 76 
has a one year case fatality of 12%,3 in studies lasting up to ten years.4 Interventional treatment 77 
(‘intervention’) by neurosurgical excision, endovascular embolization, or stereotactic radiosurgery 78 
can be used alone, or in combination, to attempt to obliterate bAVMs, dependent on their 79 
vascular anatomy.5 Because interventions may have complications6 and the untreated clinical 80 
course of unruptured bAVMs can be benign,1-4 some patients choose conservative management 81 
(without intervention). Unruptured bAVM intervention has been compared with conservative 82 
management in a concurrent control group in just one randomized trial (ARUBA 83 
[ISRCTN44013133])7-9 and only a few observational studies, all of which have shown harm from 84 
intervention in the short-term.10,11 Guidelines have endorsed both intervention and conservative 85 
management for unruptured bAVMs.12,13 Therefore, we began a study in 1999 to assess the long-86 
term outcome for adults affected by bAVM, with or without intervention, in everyday clinical 87 
practice.14,15 88 
 89 
METHODS 90 
 91 
The Scottish Intracranial Vascular Malformation (IVM) Study (SIVMS) is a prospective, population-92 
based cohort study that uses anonymized data extracts from the National Health Service Scottish 93 
Audit of IVMs (SAIVMs). SAIVMs included adults who were aged ≥16 years and resident in Scotland 94 
when first diagnosed with bAVM in 1999-2003 or 2006-2010 (www.saivms.scot.nhs.uk). The audit 95 
protocol (www.saivms.scot.nhs.uk/pdf/2008_06_SAIVMs%20protocol_v2.pdf) and research 96 
protocol (http://docdat.ic.nhs.uk) are published. SAIVMs identified patients through multiple 97 
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overlapping sources of case ascertainment that included a Scotland-wide collaborative network of 98 
neurologists, neurosurgeons, stroke physicians, radiologists, and pathologists and central registers 99 
of hospital discharges and death certificates.15 100 
 101 
Ethical approval 102 
 103 
The Multicentre Research Ethics Committee for Scotland (MREC/98/0/48) and the Fife and Forth 104 
Valley Research Ethics Committee (08/S0501/76) approved the conduct of observational studies 105 
(to which an opt-out consent policy applied) and postal questionnaire studies (which required opt-106 
in consent). 107 
 108 
Eligibility criteria 109 
 110 
In this analysis, we included adults in SIVMS with a radiographically- or pathologically-confirmed 111 
first-in-a-lifetime definite diagnosis of a bAVM in 1999-2003 or in 2006-2010 inclusive, which was 112 
unruptured when diagnosed. The term ‘bAVM’ included associated nidal/feeding arterial 113 
aneurysms, but not intracranial aneurysms remote from the bAVM its arterial supply. We 114 
classified adults as receiving intervention if they underwent any of the following treatments for 115 
their unruptured bAVM, either alone or in any combination, before the end of follow-up: 116 
microsurgical excision, stereotactic radiosurgery, or endovascular (glue or coil) embolization. We 117 
classified adults as undergoing ‘conservative management’ if they did not receive any of these 118 
interventions. Decisions about intervention were left to patients and their physicians. 119 
 120 
 121 
 122 
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Diagnostic verification 123 
 124 
Four experienced neuroradiologists verified certainty of bAVM diagnosis on diagnostic brain 125 
imaging that had been performed in clinical practice (supported by the Systematic Image Review 126 
System tool; http://www.neuroimage.co.uk/sirsinfo/). They determined surgical eloquence of 127 
nidus location16 and used catheter angiography to describe vascular anatomy10 or MRI to measure 128 
nidus size.17,18 129 
 130 
Baseline characteristics 131 
 132 
We reviewed family (general) practitioner and hospital medical records to establish demographics, 133 
medical histories, and the consequences of bAVM presentation on the Oxford Handicap Scale 134 
(OHS), which is a derivative of the modified Rankin Scale, ranging from 0 (no symptoms) to 6 135 
(death).19 We reviewed these medical records, brain imaging and reports of pathological 136 
examinations to classify the mode of bAVM presentation and clinical outcome events during 137 
follow-up. When assessing clinical events at presentation and during follow-up, we also classified 138 
whether they were definitely, possibly, or definitely not attributable to the bAVM or an 139 
intervention complication. We classified events as possibly attributable to the bAVM when clinical 140 
features were anatomically consistent with bAVM location, but another cause (e.g. ischaemic 141 
stroke) was possible and neuroradiological investigation had identified neither bAVM hemorrhage 142 
nor an alternative cause. We regarded presentations as ‘incidental’ if the adult had been 143 
asymptomatic or if we could not definitely relate their symptoms to the underlying bAVM (e.g. 144 
headache); we attributed presentations to epileptic seizure(s) if a seizure was neither 145 
symptomatic of a concomitant intracranial hemorrhage nor more likely to be due to another 146 
cause. 147 
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 148 
Follow-up 149 
 150 
The inception point for conservative management was an adult’s presentation, which was the date 151 
of symptom onset or medical consultation (if asymptomatic) that led to an investigation 152 
diagnosing the bAVM. The inception point for intervention was the date of the first intervention 153 
for an unruptured bAVM that proceeded after presentation. Follow-up occurred prospectively on 154 
an uninterrupted annual basis, using a postal questionnaire to every adult’s family practitioner and 155 
annual surveillance of family practitioner and hospital medical records, to identify outcome events 156 
that had occurred over the preceding year. Consenting participants completed postal 157 
questionnaires on each anniversary of bAVM diagnosis, to identify outcome events and assess 158 
handicap on the OHS. Two investigators (CPW or RA-SS) independently assessed symptomatic 159 
clinical outcome events,10 using all the contemporaneous clinical, radiographic and pathological 160 
records available. In attributing the mode and cause of death we reviewed death certificates, 161 
autopsy reports if performed, and clinical records and brain imaging if death occurred in hospital. 162 
Extent of bAVM obliteration was assessed from reports of angiographic brain imaging after 163 
intervention. We gave precedence to obliteration confirmed by catheter angiography, otherwise 164 
we relied on magnetic resonance angiography. 165 
 166 
Statistical methods 167 
 168 
Baseline characteristics 169 
 170 
For analyses of clinical covariates, age was a continuous variable, OHS at presentation was 171 
dichotomized into 0-1 versus 2-5, and mode of presentation was dichotomized into seizure(s) 172 
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versus other (although, if following presentation a clinical event occurred which led to 173 
intervention, this subsequent event became the mode of presentation in the intervention group). 174 
We dichotomized bAVM nidus location into deep (involving the basal ganglia, internal capsule, 175 
thalamus, hypothalamus, limbic system, or corpus callosum) versus other. We dichotomized 176 
venous drainage into exclusively deep versus other, and bAVM nidus maximum diameter into 177 
<3cm versus ≥3cm. We separately derived the bAVM Spetzler-Martin grade, which predicts the 178 
likelihood of morbidity from bAVM excision based on bAVM size, venous drainage pattern, and 179 
eloquence of surrounding brain (grade 1 lowest risk to grade 5 highest risk).16 180 
 181 
Follow-up 182 
 183 
The primary outcome was the first occurrence of handicap (OHS 2-5, signifying, “some restrictions 184 
to lifestyle, but the patient can look after themselves” or worse) sustained for at least two 185 
successive years after inception (i.e. the baseline OHS rating was not included in the outcome 186 
measure) or death (OHS 6) of any cause. The secondary outcome was non-fatal symptomatic 187 
stroke (intracranial hemorrhage, cerebral infarction, or focal neurological deficit persisting or 188 
progressing for >24 hours) or death due to the bAVM or intervention. 189 
 190 
Sample size 191 
 192 
The number of adults diagnosed with unruptured bAVM in our population over ten years 193 
determined our sample size, but the timing of our analyses during follow-up was determined by 194 
the accumulation of sufficient primary and secondary outcomes to power the multivariable model 195 
to include five important covariates without over-fitting.20 196 
 197 
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Analytical methods 198 
 199 
RA-SS conducted analyses according to a statistical analysis plan approved by the Steering 200 
Committee before data extraction (www.saivms.scot.nhs.uk/pdf/resPaper/2013_07_05_SAP.pdf). 201 
Completeness of follow-up data was quantified as a proportion of all the potential follow-up time 202 
that could have been accrued prior to death or the last available follow-up.21 Survival analyses of 203 
time to first event started at inception and stopped at the date of the first outcome or the date of 204 
censoring, whichever occurred sooner. For the primary outcome censoring occurred at last 205 
available follow-up, before which we disregarded missing OHS scores. For the secondary outcome, 206 
censoring occurred at last available follow-up or death (possibly or definitely not attributable to 207 
bAVM). Adults managed conservatively who had a secondary outcome event that led to 208 
intervention remained in the conservative management group for outcome analyses. 209 
 210 
Bivariate analyses were performed using life tables and Kaplan-Meier estimates to analyze follow-211 
up data accrued by 12 years (when ~10% of the cohort remained under follow-up22) with 212 
differences between intervention and conservative management determined by the log-rank test 213 
and hazard ratio (HR) from Cox regression, with intervention as the referent category. We pre-214 
specified multivariable analyses to adjust HRs when proportional hazards assumptions were 215 
satisfied.23 Covariates were selected from the following list, in the following order which was 216 
determined by the clinical relevance and likely completeness of the covariates, until the number of 217 
outcomes per covariate would be below ten with the addition of another covariate20: clinical 218 
influences on functional outcome ([1] age at inception, [2] mode of clinical presentation,24 and [3] 219 
baseline OHS score [for the primary outcome only]) and vascular anatomy that influences either 220 
the risk of bAVM hemorrhage ([4] bAVM nidus location and [5] bAVM venous drainage pattern1,2) 221 
or the risk of intervention ([6] maximum bAVM nidus diameter10,16). Covariates were entered 222 
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simultaneously into the regression model. In a supplementary analysis, we derived a model to 223 
predict the occurrence of intervention (using age at presentation, receipt of a catheter angiogram, 224 
and sex) and adjusted the multivariable models of the primary and secondary outcomes for these 225 
propensity scores. 226 
 227 
RA-SS used IBM SPSS Statistics (version 19.0), Stata (version 11.2), StatsDirect (version 2.7.8), and 228 
Confidence Interval Analysis software to calculate: parametric statistics for between-group 229 
comparisons when continuous data obeyed a normal distribution and non-parametric statistics 230 
when they did not; exact tests in the analysis of categorical data; and HRs with Cox regression 231 
analyses. All reported P values are two-sided (α=0·05). 232 
 233 
RESULTS 234 
 235 
Baseline characteristics 236 
 237 
During 1999-2003 and 2006-2010, 213 adults were newly diagnosed with at least one definite 238 
unruptured bAVM, of whom 204 were eligible for analysis (Figure 1). 103 underwent intervention. 239 
101 underwent conservative management (five of whom had a bleed during follow-up and 240 
subsequently underwent intervention). Adults receiving intervention were younger, more likely to 241 
present with seizure(s), more likely to have a catheter angiogram and less likely to have a 242 
maximum bAVM diameter >6cm (Table 1). 243 
 244 
 245 
 246 
 247 
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Conservative management 248 
 249 
101 adults were managed conservatively, which involved usual care (e.g. pharmacological 250 
treatment of seizures) but no intervention. In this group, embolization was attempted but did not 251 
proceed in two adults (because of spontaneous bAVM obliteration 12 days after presentation in 252 
one adult and the demonstration of unsuitable vascular anatomy on superselective angiography in 253 
another) and three adults underwent intervention for a remote intracranial aneurysm, but the 254 
bAVM was not treated. A second bAVM spontaneously obliterated 2·4 years after presentation. 255 
 256 
Intervention 257 
 258 
103 adults received their first intervention after median 13 months (inter-quartile range [IQR] 7-259 
19, range 0-97) following presentation (eFigure 1).  Embolization was attempted but did not 260 
proceed because of unsuitable vascular anatomy in four adults (subsequently embolization was 261 
possible in one and three underwent stereotactic radiosurgery). Two-thirds received single-262 
modality intervention and one-third received multi-modality intervention over median 12 months 263 
(eFigure 2 and eTable 1). 83 adults had catheter angiography and 14 had magnetic resonance 264 
angiography following their last intervention, demonstrating bAVM obliteration in 63% after 265 
single-modality and 71% following multi-modality intervention (eTable 1). Adults undergoing 266 
stereotactic radiosurgery had their most recent imaging study after mean 32±15 months following 267 
their most recent intervention. 268 
 269 
 270 
 271 
 272 
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Outcome after intervention or conservative management 273 
 274 
We followed 204 adults with bAVM who were alive at presentation for a median of 6·9 years (IQR 275 
4.0-11.0) and a total of 1,479 person-years (of 1,567 potential person-years; overall completeness 276 
94%21). The median duration of follow-up was longer after intervention (9·4 years, IQR 5·0-11·9) 277 
than during conservative management (5·2 years, IQR 3·0-9·7; p=0·002) because three-quarters of 278 
the 41 deaths occurred during conservative management (Figure 1 and eFigure 3 and eFigure 4). 279 
 280 
For the primary outcome, the proportional hazards assumption was met over the first four years 281 
of follow-up. During this time the rate of progression to the primary outcome was lower during 282 
conservative management than after intervention (36 vs. 39 events, 9.5 vs 9.8 per 100 person 283 
years, adjusted HR 0·59, 95% confidence interval [CI] 0·35-0·99; Table 2 and Figure 2), but rates 284 
were not different when subsequent time periods were analysed separately (4-8 years, 8 vs. 8 285 
events, adjusted HR 1·07, 95% CI 0·37-3·16; 8-12 years, 5 vs. 1 event, adjusted HR 4·70, 95% CI 286 
0·29-77·42). Over 12 years, the death rate was higher during conservative management than after 287 
intervention (31 vs. 10 events, 3.7 vs 1.1 per 100 person years, HR 3·64, 95% CI 1·78-7·43; eFigure 288 
3). This was unrelated to bAVM or intervention (log-rank p=0·29) but attributable to deaths from 289 
other causes (log-rank p<0·001); these differences disappeared after age-adjustment (eTable 2). 290 
 291 
For the secondary outcome, the proportional hazards assumption was met over 12 years of 292 
follow-up, during which time the rate of progression to the secondary outcome was lower during 293 
conservative management than after intervention (14 vs. 38 events, 1.6 vs 3.3 per 100 person 294 
years, adjusted HR 0·37, 95% CI 0·19-0·72; Table 2 and Figure 3), largely because of symptomatic 295 
strokes due to intervention (Figure 1), 7 of which occurred within 30 days of first intervention. 296 
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After these first events, there were 12 more secondary outcomes in the intervention group, and 297 
one during conservative management. 298 
 299 
Sensitivity and supplementary analyses 300 
 301 
In pre-specified sensitivity analyses, the association of conservative management with the primary 302 
outcome remained the same over four years after removing adults who experienced outcomes 303 
before bAVM intervention (34 vs. 39 events, 9.0 vs 9.8 per 100 person years, adjusted HR 0·58, 304 
95% CI 0·34-0·99) or when the two adults who had intervention attempted but not given were re-305 
allocated to the intervention group (34 vs. 41 events, 9.3 vs 10.0 per 100 person years, adjusted 306 
HR 0·53, 95% CI 0·32-0·90). The association with the secondary outcome was similar whether 307 
including pre-intervention clinical course in the conservative management group (18 vs. 39 events, 308 
2.1 vs 3.4 per 100 person years, unadjusted HR 0·27, 95% CI 0·16-0·47), including pre-intervention 309 
clinical course in the intervention group (14 vs. 33 events, 1.5 vs 2.8 per 100 person years, 310 
adjusted HR 0·50, 95% CI 0·25-0·98),25 including secondary outcomes that were possibly due to the 311 
bAVM (18 vs. 39 events, 2.1 vs 3.3 per 100 person years, adjusted HR 0·43, 95% CI 0·23-0·78), or 312 
reallocating the two adults who had intervention attempted but not given to the intervention 313 
group (14 vs. 38 events, 1.6 vs 3.2 per 100 person years, adjusted HR 0·42, 95% CI 0·22-0·79). 314 
 315 
We pre-specified a supplementary analysis of ARUBA’s primary outcome (the composite event of 316 
death from any cause or symptomatic stroke). However, the proportional hazards assumption was 317 
violated (eFigure 5) precluding multivariable analysis, because of the excess of deaths of any cause 318 
in the conservative management group in our study (Figure 1 and eFigure 3). 319 
 320 
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A post hoc analysis restricted to adults who were OHS 0-1 at baseline did not change the 321 
association between conservative management and the primary outcome (12 vs. 24 events, 5.5 vs 322 
9.0 per 100 person years, adjusted HR 0·42, 95% CI 0·20-0·89 over four years) or secondary 323 
outcome (7 vs. 20 events, 1.3 vs 2.5 per 100 person years, adjusted HR 0·35, 95% CI 0·14-0·87). 324 
 325 
In post hoc analyses, we found differences between the two cohort epochs in some covariates. 326 
Therefore, we added a cohort epoch term to our multivariable models, which had sufficient 327 
outcomes to allow the addition of another covariate. The strength and statistical significance of 328 
the associations in our multivariable analyses of the primary and secondary outcomes (Table 2) did 329 
not change, but the 2006-2010 cohort was associated with faster progression to the secondary 330 
outcome (27 vs. 25 events, 4.6 vs 1.8 per 100 person years, adjusted HR 2·37, 95% CI 1·28-4·36). 331 
Post hoc multivariable analyses also adjusted for scores modelled on propensity to intervention 332 
did not change the association between conservative management and the primary outcome (36 333 
vs. 39 events, 9.5 vs 9.8 per 100 person years, adjusted HR 0·50, 95% CI 0·27-0·94; eTable 3) or 334 
secondary outcome (14 vs. 38 events, 1.6 vs 3.3 per 100 person years, adjusted HR 0·39, 95% CI 335 
0·20-0·74; eTable 4). 336 
 337 
DISCUSSION 338 
 339 
In a prospective, population-based inception cohort study of adults with unruptured bAVM, we 340 
found that conservative management was associated with a lower rate of progression to sustained 341 
handicap or death of any cause over four years, and a lower risk of bAVM-related symptomatic 342 
stroke or death over 12 years, having adjusted for baseline imbalances and performed several 343 
sensitivity analyses. 344 
 345 
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One randomized controlled trial comparing conservative management with intervention for 346 
unruptured bAVMs (ARUBA) was published recently.8,9 Non-randomized observational studies and 347 
randomized trials sometimes concur,26,27 and in this case the similarities support the 348 
generalizability of the results: treated participants were similar in age, sex, incidental mode of 349 
presentation, lobar bAVM nidus location, superficial venous drainage pattern, and Spetzler-Martin 350 
grades (Table 1), and they received multi-modality intervention with the same frequency (eTable 351 
1).9 Furthermore, the association between conservative management and stroke or death related 352 
to bAVM or its intervention over 12 years in this observational study (adjusted HR 0·37, 95% CI 353 
0·19-0·72) was similar to the effect of conservative management on stroke or death of any cause 354 
over six years in the ARUBA as-randomized analysis (HR 0·27, 95% CI 0·14-0·54).9 The similarity of 355 
the results of this observational study and ARUBA and the persistent difference between the 356 
outcome of conservative management and intervention during 12-year follow-up in our study 357 
support the superiority of conservative management to intervention for unruptured bAVMs, 358 
which may deter these patients and physicians from intervention. 359 
 360 
The strengths of this study include: thorough case ascertainment15; a population-based sampling 361 
frame to maximize external validity; a concurrent control group; sufficient time to allow the 362 
effects of multi-modality intervention and stereotactic radiosurgery to be complete by the end of 363 
follow-up; internal validity from using independent imaging review and outcome assessment with 364 
reference to published criteria; minimisation of bias by using outcomes that were rated and 365 
adjudicated independently of the doctors caring for these adults in clinical practice; and 94% 366 
completeness of the entire duration of follow-up for all adults. The clinical outcome and 367 
proportions of bAVM obliterated by intervention in Scotland appear generalizable, by being at 368 
least as good as reports in systematic reviews6 and the USA Nationwide Inpatient Sample 369 
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database.28 Furthermore, the rate of hemorrhage from unruptured bAVMs (18%, 95% CI 11-30 370 
after 12 years; Figure 3) was consistent with reported rates.1,2 371 
 372 
This study also has several limitations. Our comparison of intervention and conservative 373 
management was not randomized, so selection bias led to adults undergoing intervention being 374 
younger, presenting more often with seizure(s), and having smaller AVM nidus diameters (Table 375 
1). Confounding by indication may affect our results, but the bAVM intervention group appeared 376 
to have favourable prognostic factors, and adjustment for propensity to intervention did not 377 
change our findings. Both the robustness of our findings in sensitivity analyses, as well as 378 
consistency between our findings and ARUBA9 are reassuring. The primary outcome did not 379 
include the baseline measurement of handicap (and therefore allowed recovery from initial 380 
presentation) and crucially it allowed for recovery from the known early complications after 381 
intervention by requiring handicap to be sustained for at least two successive years. The primary 382 
outcome was difficult to interpret beyond four years, because of the high frequency of bAVM-383 
unrelated deaths in the conservative management group, which was attributable to the imbalance 384 
in age between the groups at baseline. Long-term follow-up in both this study as well as the 385 
ARUBA trial is needed to establish whether the superiority of conservative management will 386 
persist or change. 387 
 388 
Conclusions 389 
Among adults diagnosed with unruptured bAVM, the use of conservative management compared 390 
with intervention was associated with better clinical outcomes over 4 years. However, longer 391 
follow-up is required to understand whether this association is persistent. 392 
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FIGURE LEGENDS 
FIGURE 1 – Flowchart of included participants. 
bAVM = arteriovenous malformation 
* Oxford Handicap Scale scores were not available for three patients. ¶ Five patients experiencing 
bAVM hemorrhage during conservative management subsequently had intervention, but 
remained in the conservative management group for analysis of the primary outcome 
FIGURE 2 – Progression to the primary outcome (first occurrence after inception of death of any 
cause or handicap [Oxford Handicap Scale Score 2-5] sustained for two or more successive years) 
during 12 years of prospective follow-up. 
Error bars represent the 95% confidence intervals of the cumulative proportions at four and 12 
years after inception. 
FIGURE 3 – Progression to the secondary outcome (first occurrence after inception of a non-fatal 
intracranial hemorrhage, cerebral infarct, or persistent/progressive non-hemorrhagic focal 
neurological deficit, or death, due to a brain arteriovenous malformation [bAVM] or 
intervention complication) during 12 years of prospective follow-up. 
Error bars represent the 95% confidence intervals of the cumulative proportions at four and 12 
years after inception. 
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TABLE 1 – Baseline characteristics of adults with a definite diagnosis of an unruptured brain 
arteriovenous malformation (bAVM). 
 Conservative 
management 
 
(n=101) 
Intervention 
 
 
(n=103) 
Significance 
(p value) 
Age at inception (mean ± SD), years  53 ± 16  41 ± 13 <0.001 
Female  39 (39%)  44 (43%) 0.551 
Mode of presentation   0.009 
 Incidental  61 (60%)  40 (39%)  
          Seizure(s)  33 (33%)  52 (50%)  
           First seizure  15    26   
  Epilepsy  18    26   
 Focal neurological deficit  7 (7%)  11 (11%)  
Presentation Oxford Handicap Scale 0-1  61 (60%)  69 (67%) 0.097 
bAVM nidus location   0.404 
 Brainstem  3 (3%)  1 (1%)  
 Cerebellum  1 (1%)  2 (2%)  
 Deep  3 (3%)  7 (7%)  
 Lobar  94 (93%)  93 (90%)  
Eloquent bAVM nidus location  50 (50%)  54 (52%) 0.676 
Maximum bAVM nidus diameter (n=182)   0.012 
 <3cm  45 (51%)  50 (54%)  
 3-6cm  36 (40%)  43 (46%)  
 >6cm  8 (9%)  0 (0%)  
Catheter angiogram done  46 (46%)  96 (93%) <0.001 
Venous drainage pattern (n=142)   0.618 
 Superficial  30 (65%)  69 (72%)  
 Both deep and superficial  13 (28%)  20 (21%)  
 Exclusively deep  3 (7%)  7 (7%)  
Spetzler-Martin Grade16 (n=142)   0.212 
 I  9 (20%)  21 (22%)  
 II  15  (33%)     36 (38%)  
 III  12  (26%)     29 (30%)  
 IV  8  (17%)     10 (10%)  
 V  2  (4%)  0 (0%)  
Co-existing intracranial aneurysms   0.236 
 Associated only  20 (20%)  19 (18%)  
 Remote and associated  1 (1%)  6 (6%)  
 Remote only  4 (4%)  2 (2%)  
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TABLE 2 – Bivariate and multivariable Cox proportional hazards analyses of the first occurrence of a primary or secondary outcome. 
 
 Primary outcome¶  Secondary outcome∫ 
 Cases 
(n) 
 Outcomes 
(n) 
 Hazard ratio 
(95% confidence interval) 
 Cases 
(n) 
 Outcomes 
(n) 
 Hazard ratio 
(95% confidence interval) 
     Unadjusted 
bivariate 
Multivariable 
adjusted* 
     Unadjusted 
bivariate 
Multivariable 
adjusted§ 
Treatment              
 Conservative 
 management 
98  36  
0·82 (0.52-1.29) 0·59 (0·35-0·99) 
 101  14  
0·31 (0·17-0·58) 0·37 (0·19-0·72) 
 Intervention 
 (referent) 
103  39   103  38  
Age at inception (per 
year increase) 
201  75  1·01 (0.99-1.03) 1·01 (0·99-1·03)  204  52  0·98 (0·96-0·99) 0·99 (0·97-1·01) 
Presentation              
 Seizure(s) 85  33  
1·04 (0.66-1.65) 0·74 (0·43-1·29) 
 85  26  
1·42 (0·82-2·44) 1·21 (0·68-2·16) 
 Other (referent) 116  42   119  26  
Presentation OHS              
 2-5 74  39  
2·23 (1.41-3.50) 2·48 (1·49-4·12) 
 -  -  
- - 
 0-1 (referent) 127  36   -  -  
bAVM location              
 Deep 10  3  
0·75 (0.24-2.39) 0·73 (0·23-2·39) 
 10  5  
1·99 (0·79-5·01) 1·71 (0·66-4·46) 
 Other (referent) 191  72   194  47  
¶ first occurrence during four years of follow-up after inception of death or handicap [Oxford Handicap Scale Score (OHS) 2-5] sustained for two or more successive years; ∫ first 
occurrence during 12 years of follow-up after inception of a non-fatal intracranial hemorrhage, cerebral infarct, or persistent / progressive non-hemorrhagic focal neurological 
deficit, or death, due to a brain arteriovenous malformation [bAVM] or intervention complication; * adjusted for intervention, age at inception, mode of presentation, bAVM 
location, and OHS at presentation; § adjusted for intervention, age at inception, mode of presentation, and bAVM location 
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FIGURE 1 – Flowchart of included participants. 
bAVM = arteriovenous malformation 
* Oxford Handicap Scale scores were not available for three patients. ¶ Five patients experiencing 
bAVM hemorrhage during conservative management subsequently had intervention, but 
remained in the conservative management group for analysis of the primary outcome 
Resident in Scotland and aged at least 16 
years at the time of a first-in-a-lifetime 
definite diagnosis of a brain arteriovenous 
malformation (bAVM) 1999-2003 [n=232] 
 
Intervention 
[n=103] 
Conservative 
management 
[n=101] 
Analyzed for secondary 
outcomes [n= 103] 
Analyzed for primary 
outcome [n=98]* 
Secondary outcomes [n=38] 
o Intracranial hemorrhage (17), 
cerebral infarct (6), non-
hemorrhagic focal neurological 
deficit (15) due to: 
• bAVM (10) 
• Intervention (28) 
Primary outcome [n=49] 
o Death (31) due to: 
• bAVM (6) 
• Other (20) 
• Possibly bAVM (5) 
o Non-fatal handicap (18) 
Analyzed for primary 
outcome [n=103] 
Primary outcome [n=48] 
o Death (10) due to: 
• bAVM (2) 
• Other (6) 
• Possibly bAVM (1) 
• Intervention (1) 
o Non-fatal handicap (38) 
Analyzed for secondary 
outcomes [n= 101] 
Secondary outcomes [n=14] 
o Intracranial hemorrhage (14),¶ 
cerebral infarct (0), non-
hemorrhagic focal neurological 
deficit (0) due to: 
• bAVM (14) 
Diagnosed following 
intracranial hemorrhage 
Eligible [n=204] 
Resident in Scotland and aged at least 16 
years at the time of a first-in-a-lifetime 
definite diagnosis of a brain arteriovenous 
malformation (bAVM) 2006-2010 [n=206] 
 
First diagnosed at 
autopsy 
Prior symptomatic intracranial hemorrhage, anatomically 
consistent with bAVM location, before bAVM diagnosis 
n=97 
n=1 
n=0 
n=108 
n=107 
n=4 
n=4 
n=117 
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FIGURE 2 – Progression to the primary outcome (first occurrence after inception of death of any 
cause or handicap [Oxford Handicap Scale Score 2-5] sustained for two or more successive years) 
during 12 years of prospective follow-up. 
 
 
 
 
 
 
 
Adults at risk 
(events in 
preceding year) 
Intervention   103 72 (30) 60 (6) 53 (1) 45 (2) 39 (2) 34 (4) 31 (2) 27 (0) 23 (1) 19 (0) 16 (0) 7 (0) 
Conservative 101 90 (8) 71 (18) 56 (7) 44 (3) 35 (3) 28 (1) 23 (3) 21 (1) 18 (3) 11 (2) 9 (0) 6 (0) 
Log Rank (Mantel-Cox) chi-square=0·01, p=0·91 
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FIGURE 3 – Progression to the secondary outcome (first occurrence after inception of a non-fatal 
intracranial hemorrhage, cerebral infarct, or persistent/progressive non-hemorrhagic focal 
neurological deficit, or death, due to a brain arteriovenous malformation [bAVM] or 
intervention complication) during 12 years of prospective follow-up. 
  
 
 
 
 
Adults at risk 
(events in 
preceding year) 
Intervention   103 73 (28) 64 (6) 57 (1) 50 (1) 45 (1) 41 (0) 37 (1) 34 (0) 30 (0) 22 (0) 18 (0) 8 (0) 
Conservative 101 96 (1) 86 (6) 73 (3) 61 (1) 53 (1) 42 (0) 36 (1) 33 (0) 28 (1) 21 (0) 15 (0) 11 (0) 
Log Rank (Mantel-Cox) chi-square=15·45, p<0·001 
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ONLINE-ONLY SUPPLEMENT 
 
eFIGURE 1 – Time to first intervention for an unruptured brain arteriovenous malformation or associated 
arterial aneurysm after initial presentation among the 103 adults in the intervention group 
 
eFIGURE 2 – Time between first and last intervention for an unruptured brain arteriovenous malformation or 
associated arterial aneurysm among the 103 adults in the intervention group 
 
eTABLE 1 – Type of intervention and extent of angiographic obliteration among the 103 adults in the 
intervention group 
 
eFIGURE 3 – Progression to death of any cause among the 204 adults with unruptured bAVM during 12 
years of prospective follow-up 
 
eTABLE 2 – Bivariate and multivariable Cox proportional hazards analyses of the first occurrence of death of 
any cause among the 204 adults with unruptured bAVM during 12 years of prospective follow-up 
 
eFIGURE 4 – Stacked bar chart of the proportions of the 204 adults with unruptured bAVM who were 
followed-up in each year on the Oxford Handicap Scale, stratified by treatment group for comparison 
 
eFIGURE 5 – Progression to death from any cause or symptomatic stroke among the 204 adults with 
unruptured bAVM during 12 years of prospective follow-up 
 
eTABLE 3 – Multivariable Cox proportional hazards analysis of the first occurrence of the primary outcome 
during four years of follow-up among the 204 adults with unruptured bAVM, adjusted for propensity score 
 
eTABLE 4 – Multivariable Cox proportional hazards analysis of the first occurrence of the secondary 
outcome during 12 years of follow-up among the 204 adults with unruptured bAVM, adjusted for propensity 
score 
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eFIGURE 1 – Time to first intervention for an unruptured brain arteriovenous 
malformation or associated arterial aneurysm after initial presentation among the 
103 adults in the intervention group. 
Each bin includes values greater than or equal to the lower limit and less than the upper 
limit. 
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eFIGURE 2 – Time between first and last intervention for an unruptured brain 
arteriovenous malformation or associated arterial aneurysm among the 103 adults 
in the intervention group. 
Each bin includes values greater than or equal to the lower limit and less than the upper 
limit. 
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eTABLE 1 – Type of intervention and extent of angiographic obliteration among the 
103 adults in the intervention group. 
 
Intervention n Completely 
obliterated 
Partially 
obliterated 
No follow-up 
imaging 
Single modality     
Stereotactic radiosurgery 28  18 (64%)  8 (29%)  2 (7%) 
Endovascular embolisation 22  10 (45%)  10 (45%)  2 (10%) 
Microsurgical excision 18  15 (83%)  1 (6%)  2 (11%) 
Sub-total 68  43 (63%)  19 (28%)  6 (9%) 
Multimodality **     
Endovascular embolisation and stereotactic radiosurgery 20  11 (55%)  9 (45%)  0 (0%) 
Endovascular embolisation and microsurgical excision 12  12 (100%)  0 (0%)  0 (0%) 
Stereotactic radiosurgery and microsurgical excision  2  2 (100%)  0 (0%)  0 (0%) 
Endovascular embolisation, microsurgical excision, and 
stereotactic radiosurgery 
 1  0 (0%)  1 (100%)  0 (0%) 
Sub-total 35  25 (71%)  10 (29%)  0 (0%) 
** p<0.01 comparing the proportion completely obliterated in four multimodality approaches 
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eFIGURE 3 – Progression to death of any cause among the 204 adults with 
unruptured bAVM during 12 years of prospective follow-up. 
 
 Adults at risk 
(events in 
preceding year) 
Conservative 101 96 (4) 90 (5) 78 (6) 66 (1) 57 (3) 45 (1) 39 (2) 35 (2) 31 (4) 24 (3) 15 (0) 11 (0) 
Intervention   103 99 (3) 94 (1) 82 (0) 72 (0) 63 (2) 59 (1) 53 (2) 50 (1) 43 (0) 32 (0) 26 (0) 12 (0) 
Log Rank (Mantel-Cox) chi-square=14·39, p<0·001 
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eTABLE 2 – Bivariate and multivariable Cox proportional hazards analyses of the 
first occurrence of death of any cause among the 204 adults with unruptured bAVM 
during 12 years of prospective follow-up. 
 
 Death of any cause 
 Cases (n)  Outcomes 
(n) 
 Hazard ratio 
(95% confidence interval) 
     Unadjusted bivariate Multivariable 
adjusted* 
Treatment       
 Conservative management 101  31  
3·64 (1·78-7·43) 1·62 (0·72-3·65) 
 Intervention (referent) 103  10  
Age at inception (per year increase) 204  41  1·07 (1·04-1·09) 1·04 (1·02-1·07) 
Presentation       
 Seizure(s) 85  11  
0·41 (0·21-0·82) 0·45 (0·20-0·98) 
 Other (referent) 119  30  
Presentation OHS       
 2-5 74  23  
3·30 (1·76-6·16) 3·50 (1·77-6·89) 
 0-1 (referent) 130  18  
* adjusted for intervention, age at inception, mode of presentation, and OHS at presentation 
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eFIGURE 4 – Stacked bar chart of the proportions of the 204 adults with unruptured 
bAVM who were followed-up in each year on the Oxford Handicap Scale, stratified 
by treatment group for comparison. 
Deaths are illustrated cumulatively so the annual case fatality rate is over-estimated. 
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eFIGURE 5 – Progression to death from any cause or symptomatic stroke among 
the 204 adults with unruptured bAVM during 12 years of prospective follow-up. 
 
 
 
 
 
 
Adults at risk 
(events in 
preceding year) 
Conservative 101 93 (7) 83 (9) 71 (7) 59 (1) 52 (2) 41 (0) 36 (2) 33 (2) 28 (5) 21 (3) 15 (0) 11 (0) 
Intervention   103 80 (22) 72 (5) 63 (2) 56 (1) 50 (1) 46 (1) 44 (0) 41 (1) 36 (0) 28 (0) 24 (0) 10 (0) 
Log Rank (Mantel-Cox) chi-square=0·20, p=0·66 
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eTABLE 3 – Multivariable Cox proportional hazards analysis of the first occurrence 
of the primary outcome during four years of follow-up among the 204 adults with 
unruptured bAVM, adjusted for propensity score. 
 
Primary outcome (over four years), adjusted for propensity score 
  Cases 
(n) 
 Outcomes 
(n) 
 Hazard ratio 
(95% confidence interval) 
      Multivariable adjusted 
Treatment       
 Conservative management  98  36  
0·50 (0·27-0·94) 
 Intervention (referent)  103  39  
Age (per year increase)  201  75  1·01 (0·99-1·03) 
Presentation       
 Seizure(s)  85  33  
0·69 (0·39-1·23) 
 Other (referent)  116  42  
bAVM location       
 Deep  10  3  
0·73 (0·22-2·41) 
 Other (referent)  191  72  
Presentation OHS       
 2-5  74  39  
2·48 (1·47-4·19) 
 0-1 (referent)  127  36  
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eTABLE 4 – Multivariable Cox proportional hazards analysis of the first occurrence 
of the secondary outcome during 12 years of follow-up among the 204 adults with 
unruptured bAVM, adjusted for propensity score. 
 
Secondary outcome (over 12 years), adjusted for propensity score 
  Cases 
(n) 
 Outcomes 
(n) 
 Hazard ratio 
(95% confidence interval) 
      Multivariable adjusted 
Treatment       
 Conservative management  101  14  
0·39 (0·20-0·74) 
 Intervention (referent)  103  38  
Age (per year increase)  204  52  0·99 (0·97-1·01) 
Presentation       
 Seizure(s)  85  26  
1·15 (0·65-2·04) 
 Other (referent)  119  26  
bAVM location       
 Deep  10  5  
1·69 (0·65-2·04) 
 Other (referent)  194  47  
 
